Hematopoietic Stem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationGraft vs Host DiseaseTransplantation ConditioningHematopoietic Stem CellsHematologic NeoplasmsStem Cell TransplantationTransplantation, AutologousTissue DonorsTransplantation ChimeraBone MarrowGraft vs Leukemia EffectWhole-Body IrradiationBone Marrow CellsPeripheral Blood Stem Cell TransplantationBusulfanLeukemiaHistocompatibilityTreatment OutcomeGraft SurvivalHistocompatibility TestingRecurrenceMyeloablative AgonistsGraft vs Tumor EffectChimerismRetrospective StudiesHematologic DiseasesLeukemia, Myeloid, AcuteStem CellsAnemia, AplasticMyelodysplastic SyndromesImmunosuppressive AgentsVidarabineLymphocyte TransfusionCord Blood Stem Cell TransplantationRemission InductionHLA AntigensHepatic Veno-Occlusive DiseasePrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsTransplantation, IsogeneicLiver TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSiblingsTransplantation ImmunologyCombined Modality TherapyTime FactorsHematopoiesisSurvival RateCytomegalovirus InfectionsSurvival AnalysisAcute DiseaseCyclophosphamideLymphocyte DepletionT-LymphocytesMice, Inbred C57BLDisease-Free SurvivalSevere Combined ImmunodeficiencyFlow CytometryFollow-Up StudiesOpportunistic InfectionsMultiple MyelomaCystitisMinor Histocompatibility AntigensKidney TransplantationImmunosuppressionLeukemic InfiltrationHematopoietic Stem Cell MobilizationAntigens, CD34Leukemia, MyeloidAntilymphocyte SerumNeoplasm, ResidualGraft RejectionSalvage TherapyLymphoproliferative DisordersCell DifferentiationBone and BonesAntineoplastic Combined Chemotherapy ProtocolsCytomegalovirusBlood Group IncompatibilityImmunocompromised HostPrognosisFatal OutcomeBronchiolitis ObliteransRisk FactorsCell TransplantationCyclosporineBone Marrow PurgingCytarabineColony-Forming Units AssayLiving DonorsRadiation ChimeraMesenchymal Stem Cell TransplantationMelphalanMycosesPrimary MyelofibrosisCell LineageHeart TransplantationCells, Cultured